Peiper M, Goedegebuure P S, Eberlein T J, Zornig C
Biological Cancer Therapy Laboratory, Department of Surgery, Brigham & Women's Hospital, Harvard Medical School, USA.
Zentralbl Chir. 1997;122(3):141-8.
In spite of modifications of the intra- and postoperative therapeutic strategy as well as new adjuvant protocols, most malignant diseases have a poor prognosis. This demonstrates the need for new approaches in tumor therapy. One alternative is adoptive immunotherapy (AIT). AIT is based on the observation that cytotoxic T-lymphocytes (CTL) may be generated with the ability to lyse autologous tumor cells in vitro and in vivo. Aim of current research activities is to determine specific tumorantigens and the clinical applicability of cell-mediated immunotherapy. The immunobiology of the cell-mediated immune response to cancer with focus on major-histocompatibility complex class I and CD8+ T cells is reviewed. Recent advances in the identification of tumor-associated and tumor-specific antigens were summarized. Previously performed clinical studies were reviewed. We examined the implications that the discovery of these antigens might have on the development of new anticancer vaccines.
尽管对术中和术后治疗策略进行了改进，并采用了新的辅助治疗方案，但大多数恶性疾病的预后仍然很差。这表明肿瘤治疗需要新的方法。一种替代方法是过继性免疫疗法（AIT）。AIT基于这样的观察结果，即细胞毒性T淋巴细胞（CTL）可以在体外和体内产生裂解自体肿瘤细胞的能力。当前研究活动的目的是确定特定的肿瘤抗原以及细胞介导免疫疗法的临床适用性。本文综述了以主要组织相容性复合体I类和CD8 + T细胞为重点的细胞介导免疫反应对癌症的免疫生物学。总结了肿瘤相关抗原和肿瘤特异性抗原鉴定方面的最新进展。回顾了以前进行的临床研究。我们研究了这些抗原的发现可能对新型抗癌疫苗开发产生的影响。
